8.60 0.00 (0.00%)
Pre-Market: 7:25AM EST
|Bid||8.58 x 3000|
|Ask||8.70 x 900|
|Day's Range||8.57 - 8.78|
|52 Week Range||3.69 - 24.00|
|Beta (3Y Monthly)||3.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.79|
HENDERSON, NV / ACCESSWIRE / February 21, 2018 / The healthcare sector provides investors with some of the biggest profit opportunities in the whole market. An oversold stock in the sector we think you ...
CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. As a result of the advent of new technologies and product offerings in other industries, healthcare customers have come to expect the same experience from healthcare companies. ), AcelRx Pharmaceuticals Inc (ACRX), and Bio Blast Pharma Ltd (ORPN) represent four healthcare companies operating with the consumer's best interests in mind.
Shares of Viking Therapeutics (NASDAQ:VKTX) are making headlines this week after an announcement from Gilead Sciences (NASDAQ:GILD), that one of its drugs did not meet the primary endpoints of its Phase 3 clinical trial. This gave a possible opening to Viking Therapeutics, which gave a boost to VKTX stock.Source: Shutterstock Does that make it a buy? Let's examine the stock a bit more closely. If you haven't heard of VKTX stock before, don't feel guilty. With a market cap of just $650 million, it's not a well-known company. It's not a Bristol-Myers Squibb (NYSE:BMY), Celgene (NASDAQ:CELG), Biogen (NASDAQ:BIIB) or another large cap biotech company. Breaking Down VKTX StockViking Therapeutics is a self-described "clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders." The company is working on several treatments, one of which includes enrolling VK2809, which is aimed at fatty liver and hypercholesterolemia, in a Phase 2 study. Gilead's Selonsertib liver treatment failed its Phase 3 clinical trial earlier this week, thus giving some hope to VKTX stock.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 U.S. Stocks That Are Coming to Life Again The company also has VK5211, "an orally available, non-steroidal SARM designed to selectively stimulate muscle and bone formation."At the end of the day, Viking Therapeutics has some intriguing developments in its pipeline. But at the same time, this is also a speculative biotech company. Investors are, to some degree, betting on a binary event. Either VKTX stock is a multi-bagger with big-time potential if it gains regulatory approval and/or is acquired by a larger company, or neither of those things happen and it's a total dud. That's the nature of the beast with young biotech stocks.Case in point? Viking Therapeutics stock doesn't have any revenue. Its pipeline is promising, but that's all investors are betting on at this point. There's no real way to evaluate the business because there is no business! At least in the traditional sense. VKTX has enough money in the bank to fund its operations for the time being, but its future hinges solely on its treatments. Trading VKTX StockHopefully the chart above doesn't seem too complex. I only wanted to lay out a few different levels and prior trends that played a role in VKTX stock over the last 12 months.Like most of the market, VKTX came into Q4 near its highs, although admittedly under some pressure already. Still, the stock was pummeled along with the S&P 500 and other major market indices as Q4 got under way. VKTX stock price bottomed near $7 on Christmas Eve and has been working higher since.VKTX stock is now over the 50-day and 21-day moving averages. For traders and investors that are going in on this, perhaps consider using a $7 as a key reference level. Below this mark and Viking Therapeutics stock could be in trouble.As much as I want to say that the stock is okay over uptrend support (purple line) and moving average support -- and really, it is -- know that this is a speculative position that is subject to extreme moves in both directions. These moves can appear overnight and there's little investors can do about it other than planning ahead with proper position sizing. * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? For those that don't want such a speculative position, consider choosing between two companies like Celgene and Gilead.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post Should You Buy Viking Therapeutics After Gilead Drug Failure? appeared first on InvestorPlace.
Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.
Companies working in the healthcare sector are tasked with meeting the growing demand for effective treatment options given that, almost every day, medical experts discover a new disease or ailment. Premier Health Group (OTC:PHGRF) (CSE:PHGI), CAS Medical Systems Inc (CASM), CorMedix Inc (NYSE American: CRMD), and Viking Therapeutics Inc (VKTX) represent four healthcare companies determined to create products to help consumers have a better life.
Viking Therapeutics shares moved higher after an analyst suggested that it could become a takeover target for Gilead following a clinical failure.
VK2809 is an agonist of the thyroid hormone receptor beta (TRβ). There are two major isoforms of the thyroid hormone receptor (TR), TRα and TRβ, which have markedly different expression patterns. TRα expression is highest in the heart and brain while TRβ expression is highest in the liver (Bookout et al., 2006).
Viking Therapeutics fell earlier this week after Citron Research released a bearish report on licensor Ligand Pharma, but shares recovered on Thursday.
Citron Research, the activist short-seller headed by Andrew Left, has dug up some nasty evidence against Ligand Pharmaceuticals Inc. (LGND). In a 23-page report, Citron accused the San Diego-based biopharmaceutical company of misleading investors, adding that its future revenue calculations are a "pipe dream." The short seller then slapped a $35 price target on the stock, implying 80% downside from the report’s publication date. After failing to successfully develop its own drugs, Ligand switched its business model to focus on collecting royalties and milestone payments from compounds and intellectual property that it licenses to other drug developers.
Ligand Pharmaceuticals stock crashed to nearly a two-year low Wednesday after short-seller Citron Research slammed the biotech stock for having "80% downside from its current levels."
Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) shares were falling Wednesday after Citron Research issued a report alleging that Ligand’s business model is a “pipe dream," saying the company is deceiving ...
HENDERSON, NV / ACCESSWIRE / January 4, 2019 / Biotech companies could be in store for a big 2019, and investors are starting to take notice. The stocks we are highlighting today all look poised for a ...
SAN DIEGO , Jan. 2, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...